MARINUS PHARMACEUTICALS, INC.
MARINUS PHARMACEUTICALS, INC. (MRNS): 1 pipeline candidate · ~7 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
7.2 months
D/E -1.95 · 4% dilution
Lead: Approved
1 candidate
N/A
N/A
A transparent, data-derived signal for MARINUS PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$42.2M
Quarterly Burn
$19.5M
Runway
7.2 mo
Revenue
$8.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| ztalmy | Approved |
Frequently asked questions
How many drug candidates are in MARINUS PHARMACEUTICALS, INC.'s pipeline?
MARINUS PHARMACEUTICALS, INC. (MRNS) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is MARINUS PHARMACEUTICALS, INC.'s lead drug candidate?
MARINUS PHARMACEUTICALS, INC.'s most advanced tracked candidate is ztalmy (Approved) for Seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD).
What is MARINUS PHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, MARINUS PHARMACEUTICALS, INC. has approximately 7.2 months of cash runway.
Who is the CEO of MARINUS PHARMACEUTICALS, INC.?
Scott Braunstein, M.D. is the chief executive officer of MARINUS PHARMACEUTICALS, INC. (MRNS).
Get the full picture on MARINUS PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.